Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience

被引：0
|
作者：
Jimenez-Zepeda, Victor [1 ]
Duggan, Peter [2 ]
Neri, Paola [2 ]
Luider, Joanne [2 ]
Tay, Jason [2 ]
Bahlis, Nizar J. [3 ]
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] TBCC, Calgary, AB, Canada
[3] Univ Calgary, Calgary, AB, Canada
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.122
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-120
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [1] CARFILZOMIB TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
    Uysal, A.
    Ozkan, M. Comert
    Soyer, N. Akad
    Sahin, F.
    Vural, F.
    Tobu, M.
    Tombuloglu, M.
    Saydam, G.
    [J]. LEUKEMIA RESEARCH, 2016, 49 : S29 - S30
  • [2] Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
    Abdallah, Al-Ola
    Dunavin, Neil
    McClune, Brian
    Shune, Leyla
    Dias, Ajoy L.
    Mahmoudjafari, Zahra
    Hochard, Erica
    McGuirk, Joseph P.
    Ganguly, Siddhartha
    [J]. BLOOD, 2018, 132
  • [3] Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Elotuzumab and Daratumumab: A Single Center Experience
    Basher, Fahmin
    Paul, Yonette
    Hoffman, James E.
    [J]. BLOOD, 2020, 136
  • [4] Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study
    Kazutaka Sunami
    Hiroyuki Murakami
    Hisashi Tagashira
    Hiroko Ueda
    Takashi Moriyama
    Tatsunori Ishikawa
    Takanori Yoshioka
    Masanori Makita
    [J]. International Journal of Clinical Oncology, 2020, 25 : 2151 - 2157
  • [5] Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study
    Sunami, Kazutaka
    Murakami, Hiroyuki
    Tagashira, Hisashi
    Ueda, Hiroko
    Moriyama, Takashi
    Ishikawa, Tatsunori
    Yoshioka, Takanori
    Makita, Masanori
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (12) : 2151 - 2157
  • [6] Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
    Uysal, Ayse
    Akad Soyer, Nur
    Ozkan, Melda
    Sahin, Fahri
    Vural, Filiz
    Tobu, Mahmut
    Tombuloglu, Murat
    Saydam, Guray
    [J]. TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (01) : 80 - 83
  • [7] RELAPSED AND REFRACTORY MULTIPLE MYELOMA, EVOLUTION AND COMPLICATIONS SINGLE CENTER EXPERIENCE
    Ionita, I.
    Cheveresan, L.
    Iordache, M.
    Calamar, D.
    Ionita, C.
    Oros, D.
    Ionita, M.
    Ionita, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 796 - 796
  • [8] Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma
    Chehab, Sarah
    Panjic, Elyse Hall
    Gleason, Charise
    Lonial, Sagar
    Nooka, Ajay K.
    [J]. FUTURE ONCOLOGY, 2018, 14 (30) : 3111 - 3121
  • [9] Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma
    Chen, Pingping
    Ma, Jiexian
    Qian, Wensi
    Wu, Min
    Shen, Lin
    Xie, Yanhui
    [J]. MINERVA PEDIATRICS, 2024, 76 (01): : 121 - 123
  • [10] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    [J]. Drugs, 2017, 77 : 2013 - 2024
12345